Open Access

Interaction and cross-resistance of cisplatin and pemetrexed in malignant pleural mesothelioma cell lines

  • Authors:
    • Miyako Kitazono-Saitoh
    • Yuichi Takiguchi
    • Satoru Kitazono
    • Hironori Ashinuma
    • Atsushi Kitamura
    • Yuji Tada
    • Katsushi Kurosu
    • Emiko Sakaida
    • Ikuo Sekine
    • Nobuhiro Tanabe
    • Masatoshi Tagawa
    • Koichiro Tatsumi
  • View Affiliations

  • Published online on: May 4, 2012     https://doi.org/10.3892/or.2012.1799
  • Pages: 33-40
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Although cisplatin and pemetrexed are key drugs in the treatment of malignant pleural mesothelioma, their drug-drug interactions, cross-resistance and resistance mechanisms in malignant pleural mesothelioma are not well understood. In the present study, the interaction of these 2 agents was determined by clonogenic assays followed by isobologram analysis of 4 human malignant pleural mesothelioma cell lines. The cell lines were exposed to the agents using a stepwise dose-escalation method to establish drug-resistant sublines. Thymidylate synthase mRNA expression was evaluated in the drug-resistant sublines. As a consequence, cisplatin and pemetrexed had synergistic effects in 3 cell lines and an additive effect in the fourth cell line. The former 3 cell lines showed similar pemetrexed sensitivity in the parental cells and their cisplatin-resistant sublines, whereas the fourth cell line exhibited cross-resistance. In contrast, cisplatin had diverse effects on pemetrexed-resistant sublines. High thymidylate synthase expression did not correlate with natural pemetrexed resistance. Elevated thymidylate synthase expression correlated with acquired pemetrexed resistance in 2 sublines. In conclusion, cisplatin and pemetrexed showed synergistic activity and no cross-resistance in 3 of the 4 malignant pleural mesothelioma cell lines, suggesting the clinical relevance of their combination in chemotherapy. Thymidylate synthase expression did not necessarily correlate with pemetrexed resistance. The information together with the experimental model presented here would be useful for further investigating therapeutic targets of malignant mesothelioma.

Related Articles

Journal Cover

July 2012
Volume 28 Issue 1

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Kitazono-Saitoh, M., Takiguchi, Y., Kitazono, S., Ashinuma, H., Kitamura, A., Tada, Y. ... Tatsumi, K. (2012). Interaction and cross-resistance of cisplatin and pemetrexed in malignant pleural mesothelioma cell lines. Oncology Reports, 28, 33-40. https://doi.org/10.3892/or.2012.1799
MLA
Kitazono-Saitoh, M., Takiguchi, Y., Kitazono, S., Ashinuma, H., Kitamura, A., Tada, Y., Kurosu, K., Sakaida, E., Sekine, I., Tanabe, N., Tagawa, M., Tatsumi, K."Interaction and cross-resistance of cisplatin and pemetrexed in malignant pleural mesothelioma cell lines". Oncology Reports 28.1 (2012): 33-40.
Chicago
Kitazono-Saitoh, M., Takiguchi, Y., Kitazono, S., Ashinuma, H., Kitamura, A., Tada, Y., Kurosu, K., Sakaida, E., Sekine, I., Tanabe, N., Tagawa, M., Tatsumi, K."Interaction and cross-resistance of cisplatin and pemetrexed in malignant pleural mesothelioma cell lines". Oncology Reports 28, no. 1 (2012): 33-40. https://doi.org/10.3892/or.2012.1799